Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from the Phase IA study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell malignancies. The abstract titled "The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity in Patients with Relapsed/Refractory B-Cell Malignancies: Results from a Phase I study" is being presented by Nathan Fowler, MD at the 2010 Annual Meeting of the American Society of Hematology (ASH) today at 8:15 am in Orlando, FL.

Data Results from the Phase IA Study of PCI-32765The study enrolled 56 relapsed or refractory patients with a variety of B cell malignancies to this multi-cohort dose-escalation trial. Forty-eight of these patients are evaluable for response. The response by disease is captured below in the table.

The Phase IA study enrolled patients with multiple disease histologies including CLL/SLL, follicular lymphoma, mantle cell lymphoma, DLBCL, Marginal/Malt and Waldenstrom.  The progression-free survival varies by histology.  We have described the time on study results by histology.  Please refer to our website at http://ir.pharmacyclics.com/events.cfm to review the slides presented by Dr. Nathan Fowler at the 2010 Annual Meeting of the American Society of Hematology.NCRSDPDNE*TETE*ORR % of ITT**

ORR % of Eval**

ASCO 2010 ORR% of Eval**Chronic/Small  Lymphocytic Leukemia (CLL/SLL)16

1

8**2

0

2

1

56%**

(9/16)

69%**

(9/13)82%**

(9/11)Follicular Lymphoma (FL)16

1

3

5

4

325%

(4/16)

31%

(4/13)

27%

'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
(Date:3/27/2015)... -- Report Details  New study ... What does the future hold for top ... brand new report shows you potential revenues to 2025, ... Our 242-page report provides 185 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused ... (TLR8) candidates for the treatment of cancer, respiratory ... randomized, placebo controlled clinical trial evaluating VTX-1463 for ... that VTX-1463 significantly improved allergy symptoms based on ...
... R.I., Oct. 7 CVS Caremark ... it has appointed Jonathan C. Roberts as Chief ...  Roberts, who is currently Executive Vice President, Rx ... assume the leadership of PBM operations, mail service ...
Cached Medicine Technology:VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2CVS Caremark Appoints Jonathan C. Roberts as PBM Chief Operating Officer 2
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 One in ... according to research presented today at the American Orthopaedic ... The study examined the long term success of surgery ... “We examined survey data from 242 patients who underwent ... Justin P. Roe, MBBS, FRACS, from North Sydney Orthopaedic ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... -- Preliminary results from the first-of-its-kind Clinical Evaluation ... today at the Society of Gastroenterology Nurses and Associates, ... The study indicated that while there are written ... participated in the study, significant variation in manual reprocessing ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... Alcon and Initial Payments from New Galderma Collaboration ... May 18 NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class anti-infective products for the treatment and ... causing resistance, reported today its financial results and ...
... Dad and Give Back To A Worthy CauseLOS ANGELES , ... figures in their lives and Teleflora, the world,s leading ... run with its Father,s Day product line-up. Adding extra batting ... Prostate Cancer Foundation (PCF), to help raise awareness for prostate cancer ...
... - New data to be presented on Abbott,s market-leading ... Abbott,s next-generation drug eluting stent in developmentBARCELONA, Spain, May ... announced the company,s schedule of major events and news ... 22. These include the presentation of new data from ...
Cached Medicine News:Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 2Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 3Health News:Abbott Announces EuroPCR 2009 Activities 2Health News:Abbott Announces EuroPCR 2009 Activities 3Health News:Abbott Announces EuroPCR 2009 Activities 4
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... Save precious time and gain efficiency ... Lab Automation System (LAS), the high-throughput ... sample-processing capabilities. The Olympus OLA2500 LAS ... designed for medium- to high-volume laboratories. ...
The Freedom EVO series platform offers a choice of flexible, scalable solutions for current and future application needs....
Medicine Products: